FEDERAL GRANT AWARD SUMMARY Ometa Labs LLC received a $675,609 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to develop an advanced bioinformatics platform for large-scale untargeted metabolomics analysis. The two-year project, which commenced August 1, 2025 and concludes July 31, 2027, aims to rebuild existing software into a next-generation platform capable of identifying and...
Omicscraft LLC received a $256,000 Project Grant from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041) to develop a cloud-based platform for analysis of untargeted metabolomics data. The platform will provide users an interactive modular interface to build customized pipelines for metabolomics data analysis from February 15, 2022 through July 31, 2022. Key deliverables include innovative computational methods for...
This $255,706 National Science Foundation SBIR Phase I Project Grant to Metfora LLC supports the development of a novel multiplexed metabolite diagnostic blood test for early detection of chronic diseases. The NSF Technology, Innovation, and Partnerships program aims to advance science and engineering solutions to national challenges through innovation and partnerships. Specifically, Metfora will use mass spectrometry and artificial intelligence to analyze specific panels of circulating...
Sinopia Biosciences Inc. received a $285,599 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to develop a metabolomics-enabled artificial intelligence/machine learning (AI/ML) platform for discovering new cancer drug treatments and enhancing drug sensitivity. The award, dated September 22, 2025, with completion targeted for August 31, 2027, supports the company's Phase I efforts to expand upon preliminary findings demonstrating...
Federal Grant Award Summary Sinopia Biosciences Inc. received a $350,000 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded August 1, 2025, with completion targeted for July 31, 2026. The award supports the development of neural network models and computational workflows to enable efficient metabolomic characterization of large compound libraries for data-driven drug discovery (D4). Sinopia...
Federal Project Grant Award Summary Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) received a $306,872 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period August 1, 2025 through July 31, 2026. The award supports development of a commercial prototype for an ultrahigh-throughput biocatalyst evolution platform that combines precision nanoliter fluid handling, label-free...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to advance the field of native mass spectrometry (MS) analysis. The $316,825 award to Massmatrix Inc., effective May 1, 2025 through April 30, 2026, will fund the development of an innovative intact mass deconvolution method to significantly improve the speed, accuracy, and user-friendliness of protein and nucleic acid molecular...
Federal Grant Award Summary Precision Quantomics, Inc. received a $570,888 Phase I Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, effective August 15, 2025, through August 14, 2026. The grant funds the development of recombinant human enzyme panels designed to characterize drug metabolism across genetically diverse US patient populations. The project addresses a critical gap in current drug development practices by creating...
Federal Project Grant Award Summary Chemia Biosciences, Inc. received a $781,502 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to develop NatDiscovery, a computational platform for identifying novel non-ribosomal peptides from complex mass spectrometry datasets. The award, effective July 1, 2025 through June 30, 2028, supports the integration of genome mining with computational...
Federal Grant Award Summary Millennial Materials & Devices Inc. received a $306,872 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on August 1, 2025, with a completion date of July 31, 2026. The company is developing a 3D printed integrated sample preparation and chromatography platform designed to process limited-volume complex biological samples for proteomics research. The platform utilizes custom 3D printable carbon microbead...
METABOQUEST: A SUITE OF TOOLS FOR METABOLITE ANNOTATION - METABOQUEST: A SUITE OF TOOLS FOR METABOLITE ANNOTATION PROJECT SUMMARY METABOLOMICS AIMS AT HIGH THROUGHPUT DETECTION, QUANTIFICATION, AND IDENTIFICATION OF METABOLITES IN BIOLOGICAL SAMPLES. THE USE OF LIQUID CHROMATOGRAPHY COUPLED WITH MASS SPECTROMETRY (LC-MS) HAS RISEN IN PROMINENCE IN THE FIELD OF METABOLOMICS DUE TO ITS ABILITY TO ANALYZE A SIZABLE NUMBER OF METABOLITES WITH A LIMITED AMOUNT OF BIOLOGICAL MATERIAL. HOWEVER, IN A TYPICAL UNTARGETED METABOLOMICS ANALYSIS OF HUMAN SAMPLES BY LC-MS, ABOUT 70% OF THE DETECTED PEAKS REPRESENT UNKNOWN ANALYTES MAINLY BECAUSE EXISTING MASS SPECTRAL LIBRARIES COVER ONLY A SMALL FRACTION OF KNOWN COMPOUNDS, BUT ALSO DUE TO UNCERTAINTY IN PEAK PICKING, ALIGNMENT OF PEAKS, AND RECOGNIZING ISOTOPIC PEAKS AND ADDUCT FORMS. THESE CHALLENGES HAVE KEPT AT BAY THE PACE OF DEVELOPMENT OF DATA ANALYTICS PIPELINES FOR METABOLOMICS AND ITS INTEGRATION WITH OTHER OMICS STUDIES. THE GOAL OF THIS PHASE II SBIR PROPOSAL IS TO MAKE METABOLOMICS STUDIES ON A PAR WITH OTHER OMICS STUDIES SUCH AS GENOMICS, TRANSCRIPTOMICS, AND PROTEOMICS, FOR WHICH WELL-ESTABLISHED PIPELINES ARE AVAILABLE. BY DOING SO, WE WILL ACCELERATE THE ROLE OF METABOLOMICS IN SYSTEMS BIOLOGY APPROACHES FOR VARIOUS APPLICATIONS INCLUDING BIOMARKER AND DRUG DISCOVERY. TO ACHIEVE THIS GOAL, WE PROPOSE TO DEVELOP A CLOUD-BASED PLATFORM THAT ALLOWS CUSTOMERS TO BUILD PIPELINES FOR ANALYSIS OF LC-MS-BASED UNTARGETED METABOLOMICS DATA, STARTING FROM PEAK DETECTION TO METABOLITE ANNOTATION. THIS WILL BE ACCOMPLISHED BY IMPLEMENTING A SUITE OF INNOVATIVE TOOLS THAT CAN BE ASSEMBLED INTO CUSTOMIZED PIPELINES AND BY ENHANCING METABOLITE ANNOTATION ACCURACY THROUGH INTEGRATION OF INFORMATION DERIVED FROM MULTIPLE RESOURCES INCLUDING COMPOUND DATABASES, PATHWAYS, BIOCHEMICAL NETWORKS, AND MASS SPECTRAL LIBRARIES. AIM 1 OF THIS PROPOSAL WILL FOCUS ON DEVELOPING A SUITE OF TOOLS TO ENABLE: (1) PEAK DETECTION, ALIGNMENT, AND QUALITY ASSESSMENT; (2) ADDUCT AND ISOTOPIC PEAK RECOGNITION; (3) MASS-BASED SEARCH AGAINST MULTIPLE COMPOUND DATABASES; (4) EXPERT-BASED EVALUATION OF PUTATIVE IDS; (5) ISOTOPIC PATTERN ANALYSIS; (6) NETWORK-BASED EVALUATION OF PUTATIVE IDS; (7) SPECTRAL MATCHING OF MS/MS DATA AGAINST EXPERIMENTAL AND IN- SILICO FRAGMENTATION PATTERNS; (8) DEEP LEARNING-BASED PREDICTION OF COMPOUND FINGERPRINTS; AND (9) INTEGRATIVE ASSESSMENT OF PUTATIVE METABOLITE IDS VIA A PROBABILISTIC MODEL. AIM 2 WILL ASSEMBLE THE TOOLS DEVELOPED IN AIM 1 INTO A CLOUD-BASED PLATFORM, METABOQUEST, WHICH PROVIDES USERS WITH INTERACTIVE VISUALIZATION OF PEAKS, ISOTOPIC PATTERNS, NETWORKS, AND MASS SPECTRA. FURTHERMORE, AIM 2 WILL FOCUS ON INTEGRATING INTO METABOQUEST A PIPELINE BUILDER THAT ALLOWS USERS TO CREATE PIPELINES BY LINKING MODULES AND RUN THEM REMOTELY THROUGH A MODULAR INTERACTIVE WEB INTERFACE. AIM 3 WILL PERFORM A COMPREHENSIVE EVALUATION OF METABOQUEST IN TERMS OF METABOLITE ANNOTATION ACCURACY, NUMBER OF ANNOTATED METABOLITES, AND COMPUTATIONAL EFFICIENCY COMPARED TO OTHER EXISTING TOOLS. ACCURACY IN METABOLITE ANNOTATION WILL BE EVALUATED VIA EXPERIMENTAL METHODS IN WHICH MS/MS DATA FROM UNKNOWN ANALYTES AND REFERENCE COMPOUNDS ARE COMPARED, AND BY USING LC-MS/MS DATA FROM MULTIPLE METABOLOMICS STUDIES THAT CONSIST OF GROUND-TRUTH INFORMATION. SUCCESSFUL IMPLEMENTATION AND VALIDATION OF METABOQUEST WILL CONTRIBUTE TO ADDRESSING THE MAJOR BOTTLENECK IN METABOLOMICS - METABOLITE IDENTIFICATION, THEREBY ELIMINATING THE NEED FOR MANUAL VERIFICATION OF PUTATIVE METABOLITE IDS AND ENHANCING THE CONTRIBUTION OF METABOLOMICS STUDIES, SPECIFICALLY IN DISEASE BIOMARKER AND DRUG DISCOVERY.